Pacira BioSciences, Inc.
PCRX
$23.04
$0.200.88%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.57% | 3.63% | 3.14% | 2.25% | 3.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.57% | 3.63% | 3.14% | 2.25% | 3.08% |
| Cost of Revenue | 0.02% | -8.91% | -16.21% | -14.07% | -14.06% |
| Gross Profit | 5.88% | 7.66% | 9.82% | 7.97% | 9.38% |
| SG&A Expenses | 21.72% | 25.39% | 23.72% | 20.23% | 14.12% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.96% | 15.78% | 10.83% | 8.19% | 4.11% |
| Operating Income | -72.75% | -71.51% | -41.53% | -32.32% | -3.36% |
| Income Before Tax | 119.35% | 126.74% | 176.17% | -205.97% | -166.83% |
| Income Tax Expenses | -77.50% | -73.01% | -43.07% | -43.42% | 13.85% |
| Earnings from Continuing Operations | 104.95% | 107.07% | 123.63% | -300.43% | -247.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 104.95% | 107.07% | 123.63% | -300.43% | -247.19% |
| EBIT | -72.75% | -71.51% | -41.53% | -32.32% | -3.36% |
| EBITDA | -32.61% | -32.62% | -18.52% | -9.64% | 2.38% |
| EPS Basic | 105.66% | 107.37% | 123.74% | -301.59% | -247.83% |
| Normalized Basic EPS | -83.67% | -77.30% | -44.82% | -38.86% | 4.67% |
| EPS Diluted | 105.17% | 106.76% | 122.13% | -307.43% | -255.74% |
| Normalized Diluted EPS | -83.00% | -75.99% | -42.23% | -33.96% | 11.92% |
| Average Basic Shares Outstanding | -6.66% | -3.63% | -1.78% | -0.80% | -0.37% |
| Average Diluted Shares Outstanding | -9.59% | -9.34% | -7.69% | -9.53% | -7.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |